New, tolerable γ-secretase inhibitor takes desmoid down a notch

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Solid tumors represent a significant area of oncological research.
• The Notch pathway plays a role in various cancers.
• γ-secretase inhibitors are being investigated for anti-cancer properties.

Purpose of the Study:

• To evaluate the safety and tolerability of PF-03084014, an oral reversible γ-secretase inhibitor.
• To assess the biological activity of PF-03084014 by measuring Notch pathway inhibition.
• To explore the efficacy of PF-03084014 in patients with solid tumor malignancies, particularly desmoid tumors.

Main Methods:

• Phase I clinical trial design.
• Administration of oral PF-03084014 to patients with solid tumors.
• Assessment of drug tolerability and adverse events.
• Monitoring of peripheral blood biomarkers for Notch pathway inhibition.
• Evaluation of tumor response rates.

Main Results:

• PF-03084014 demonstrated good drug tolerability in the patient cohort.
• Evidence of target engagement was confirmed through Notch pathway inhibition in peripheral blood.
• A notable and unexpectedly high response rate was observed in patients with desmoid tumors.

Conclusions:

• PF-03084014 is a tolerable oral γ-secretase inhibitor with demonstrated biological activity.
• The drug shows promising activity in desmoid tumors, warranting further investigation.
• This trial supports further development of PF-03084014 for specific cancer types.